Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

Core Insights - Mirum Pharmaceuticals has initiated the BLOOM Phase 2 clinical study for MRM-3379 targeting Fragile X syndrome (FXS) [1] - FXS is the most common inherited form of intellectual disability and autism spectrum disorder, affecting approximately 50,000 males in the U.S. and E.U. [1] - Currently, there are no approved therapies for Fragile X syndrome [1]